Key Details
Price
$18.71Last Dividend
$0.25PE Ratio
27.12Annual ROE
28.97%Beta
0.50Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Sep 8, 2015Next split:
N/ARecent split:
Jun 3, 2014Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US).
Zai Lab Limited and Innoviva Specialty Therapeutics have received approval from China's NMPA for Zai Lab's NDA for XACDURO® (sulbactam-durlobactam) for the treatment of HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus comp.
Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been a lot of movement at the company over the past 12-18 months on myriad fronts.
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FAQ
- What is the ticker symbol for Innoviva?
- Does Innoviva pay dividends?
- What sector is Innoviva in?
- What industry is Innoviva in?
- What country is Innoviva based in?
- When did Innoviva go public?
- Is Innoviva in the S&P 500?
- Is Innoviva in the NASDAQ 100?
- Is Innoviva in the Dow Jones?
- When was Innoviva's last earnings report?
- When does Innoviva report earnings?
- Should I buy Innoviva stock now?